Published in Genome Biol on January 01, 2007
Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res (2012) 2.48
Immune regulation of cancer. J Clin Oncol (2010) 1.99
Gene expression profiling of cutaneous wound healing. J Transl Med (2007) 1.91
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res (2012) 1.46
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res (2008) 1.38
Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics (2009) 1.34
Dendritic cells and immunity against cancer. J Intern Med (2011) 1.32
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res (2012) 1.31
Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer (2011) 1.19
Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC Med Genomics (2011) 1.17
Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med (2011) 1.15
Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines (2010) 1.15
Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol (2009) 1.13
Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res (2011) 1.10
Management of superficial basal cell carcinoma: focus on imiquimod. Clin Cosmet Investig Dermatol (2009) 1.08
The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother (2009) 1.06
Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists. BMC Immunol (2007) 1.01
Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol Immunother (2011) 0.93
Potency analysis of cellular therapies: the emerging role of molecular assays. J Transl Med (2007) 0.88
GM-CSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells. J Transl Med (2008) 0.86
A genetic inference on cancer immune responsiveness. Oncoimmunology (2012) 0.86
Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments. J Transl Med (2011) 0.85
Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept. OMICS (2011) 0.83
New take on comparative immunology: relevance to immunotherapy. Immunotherapy (2009) 0.82
Dendritic cell subsets as vectors and targets for improved cancer therapy. Curr Top Microbiol Immunol (2011) 0.79
Global transcriptional analysis for biomarker discovery and validation in cellular therapies. Mol Diagn Ther (2009) 0.79
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology (2017) 0.77
Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice. PLoS One (2015) 0.77
Reflections upon human cancer immune responsiveness to T cell-based therapy. Cancer Immunol Immunother (2012) 0.76
Turning laboratory findings into therapy: a marathon goal that has to be reached. Pol Arch Med Wewn (2009) 0.75
Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunol Immunother (2016) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 19.15
NK cell recognition. Annu Rev Immunol (2005) 14.40
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
High-fidelity mRNA amplification for gene profiling. Nat Biotechnol (2000) 6.97
Analysis of gene expression data using BRB-ArrayTools. Cancer Inform (2007) 6.09
Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature (2005) 5.50
Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med (2003) 4.35
Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med (2006) 3.49
Interleukin-32: a cytokine and inducer of TNFalpha. Immunity (2005) 3.39
IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci U S A (2005) 2.46
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol (2002) 1.88
Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol (2003) 1.81
Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology (2003) 1.80
Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci U S A (2006) 1.77
Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol (2002) 1.74
Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59. Science (1992) 1.68
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
RNA amplification for successful gene profiling analysis. J Transl Med (2005) 1.55
Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst (2000) 1.53
Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood (2004) 1.47
Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst (2005) 1.46
Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B. J Biol Chem (2004) 1.34
Is cancer dangerous to the immune system? Semin Immunol (1996) 1.31
The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol (2005) 1.31
Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood (2004) 1.29
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol (2005) 1.22
Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J Transl Med (2006) 1.21
A regulatory role for CD37 in T cell proliferation. J Immunol (2004) 1.20
The roles of interleukin-15 receptor alpha: trans-presentation, receptor component, or both? Int J Biochem Cell Biol (2005) 1.18
Treatment of lentigo maligna with topical imiquimod. Br J Dermatol (2003) 1.17
Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol (2005) 1.16
CD5 inhibits signaling at the immunological synapse without impairing its formation. J Immunol (2003) 1.06
The Wiskott-Aldrich syndrome protein: forging the link between actin and cell activation. Immunol Rev (2003) 1.06
Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol (2005) 1.05
Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J Cutan Pathol (2005) 1.04
The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol (2003) 1.04
Melanoma-restricted genes. J Transl Med (2004) 1.03
Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J Immunol (2000) 1.02
Differential expression of the granzymes A, K and M and perforin in human peripheral blood lymphocytes. Int Immunol (2005) 1.00
Active-specific immunization against melanoma: is the problem at the receiving end? Semin Cancer Biol (2003) 1.00
Imiquimod: a cytokine inducer. J Am Acad Dermatol (2002) 0.97
Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream. J Transl Med (2007) 0.96
Activation of monocytic cells through Fc gamma receptors induces the expression of macrophage-inflammatory protein (MIP)-1 alpha, MIP-1 beta, and RANTES. J Immunol (2002) 0.96
Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms. J Transl Med (2005) 0.95
Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg (2003) 0.94
The granzyme B-serglycin complex from cytotoxic granules requires dynamin for endocytosis. Blood (2004) 0.92
Signaling T-cell survival and death by IL-2 and IL-15. Am J Transplant (2005) 0.91
Immunology: how do T cells recognize antigen? Curr Biol (2005) 0.89
Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol (2003) 0.88
Human cathepsin W, a cysteine protease predominantly expressed in NK cells, is mainly localized in the endoplasmic reticulum. J Immunol (2001) 0.88
Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. Transplantation (2002) 0.86
CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients. Transplantation (2003) 0.85
A balanced review of the status T cell-based therapy against cancer. J Transl Med (2005) 0.84
Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol (2005) 0.83
Introduction to the series. Danger model of immunity. Scand J Immunol (2001) 0.82
Imiquimod. Drugs Today (Barc) (1999) 0.77
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Analysis of gene expression data using BRB-ArrayTools. Cancer Inform (2007) 6.09
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (2013) 5.09
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity (2013) 2.86
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res (2007) 2.69
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet (2009) 2.58
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med (2010) 2.57
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA (2011) 2.28
Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol (2005) 2.24
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol (2007) 2.10
The National Cancer Institute Thyroid fine needle aspiration state of the science conference: a summation. Cytojournal (2008) 2.05
Lost in Translation: Obstacles to Translational Medicine. J Transl Med (2004) 2.03
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat (2011) 1.99
ABCG2: a perspective. Adv Drug Deliv Rev (2008) 1.97
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol (2011) 1.93
Gene expression profiling of cutaneous wound healing. J Transl Med (2007) 1.91
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy. Blood (2009) 1.88
Quantitative real-time PCR: a powerful ally in cancer research. Trends Mol Med (2003) 1.88
MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med (2009) 1.85
What's next in translational medicine? Clin Sci (Lond) (2007) 1.85
In support of descriptive studies; relevance to translational research. J Transl Med (2007) 1.82
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res (2009) 1.81
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol (2002) 1.74
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
The dual role of IL-10. Trends Immunol (2003) 1.72
Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc Natl Acad Sci U S A (2002) 1.72
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Clonal persistence and evolution during a decade of recurrent melanoma. J Invest Dermatol (2006) 1.69
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
The immunologic constant of rejection. Trends Immunol (2008) 1.62
Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res (2012) 1.61
Investigation of residual hepatitis C virus in presumed recovered subjects. Hepatology (2012) 1.61
Cytokines and Immune Response in the Tumor Microenvironment. J Immunother (1991) (2001) 1.59
Obstacles and opportunities in translational research. Nat Med (2005) 1.59
Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med (2008) 1.57
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med (2010) 1.57
Common cancer biomarkers. Cancer Res (2006) 1.56
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst (2002) 1.56
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother (2003) 1.55
What have we learned from cancer immunotherapy in the last 3 years? J Transl Med (2014) 1.52
Combined breast ductal lavage and ductal endoscopy for the evaluation of the high-risk breast: a feasibility study. J Surg Oncol (2006) 1.51
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol (2011) 1.51
An immunologic portrait of cancer. J Transl Med (2011) 1.50
DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med (2008) 1.49
Research translation: a new frontier for clinical laboratories. Clin Chem Lab Med (2006) 1.48
Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol (2002) 1.48